Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab

In light of positive efficacy and safety findings from the IMbrave150 trial of atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC). Several additional trials are ongoing that combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chiun, Rimassa, Lorenza, Sun, Hui-Chuan, Vogel, Arndt, Kaseb, Ahmed O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Immunotherapy in Hepatocellular Carcinoma: A New Kid on the Block
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327224/
https://www.ncbi.nlm.nih.gov/pubmed/34377156
http://dx.doi.org/10.1177/17588359211031141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327224/
https://www.ncbi.nlm.nih.gov/pubmed/34377156
http://dx.doi.org/10.1177/17588359211031141

Ejemplares similares